Aditxt initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Aditxt with a Buy rating and $4 price target. Aditxt is a biotechnology company focused on improving the health of the immune system through immune mapping and reprogramming to provide a personalized comprehensive profile of the immune system, Kapoor tells investors in a research note.